|  |  |  |  |
| --- | --- | --- | --- |
| **Supplementary** **Table 4.** Summary of TEAEs of possible decreased sympathetic functionthrough week 80 (treatment + follow-up periods) | | | |
| **N (%) of patients** | **Tanezumab**  **5 mg**  **(n = 92)** | **Tanezumab**  **10 mg**  **(n = 93)** | **Celecoxib**  **200 mg**  **(n = 92)** |
| Any TEAE | 5 (5.4) | 5 (5.4) | 9 (9.8) |
| Specific TEAE\*  Bradycardia  Diarrhea  Nausea  Abdominal discomfort  Orthostatic hypotension  Presyncope  Vomiting  Dizziness postural  Syncope | 2 (2.2)  2 (2.2)  2 (2.2)  0  1 (1.1)  0  0  0  0 | 0  1 (1.1)  1 (1.1)  0  2 (2.2)  0  0  0  1 (1.1) | 1 (1.1)  3 (3.3)  1 (1.1)  2 (2.2)  1 (1.1)  1 (1.1)  1 (1.1)  1 (1.1)  0 |
| Terms included in this analysis were: abdominal discomfort; anal incontinence; anhidrosis; blood pressure orthostatic decreased; bradycardia; diarrhea; dizziness postural; early satiety; ejaculation delayed; ejaculation disorder; ejaculation failure; heart rate decreased; hypertonic bladder; hypohidrosis; micturition urgency; nausea; nocturia; orthostatic hypotension; pollakiuria; presyncope; respiratory distress; respiratory failure; sinus bradycardia; syncope; urinary hesitation; urinary incontinence; vomiting. \*Patients could have more than one specific TEAE of possible decreased sympathetic function. TEAE = treatment-emergent adverse event.  TEAE = treatment-emergent adverse event. | | | |